Bad Blood
NATIONAL BESTSELLER • The gripping story of Elizabeth Holmes and Theranos—one of the biggest corporate frauds in history—a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword covering her trial and sentencing, bringing the story to a close.“Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book ReviewIn 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.
The Visionary's Audacious Dream
Elizabeth Holmes, a charismatic Stanford dropout, founded Theranos with a revolutionary promise: to perform hundreds of medical tests using just a single drop of blood from a finger prick. Inspired by a fear of needles and a desire to democratize healthcare, she channeled the persona of Steve Jobs to attract massive investment. Holmes envisioned a world where her Edison device would be in every home, providing early detection for various diseases. This grand vision allowed her to bypass traditional medical scrutiny, building a multibillion-dollar valuation on little more than a compelling narrative and a drive to change the world, despite having no medical background or proven technology.
A Fortress Built on Secrecy
As Theranos grew, Holmes and her partner Sunny Balwani established an intense culture of secrecy and intimidation. Employees were forced to sign draconian non-disclosure agreements, and the company was heavily compartmentalized to prevent staff from seeing the full picture of the failing technology. Dissent was met with immediate termination or legal threats, creating an environment of fear where no one dared to point out that the Edison device simply did not work. This internal paranoia ensured that the outside world, including a high-profile board of directors filled with former government officials, remained completely unaware of the technical dysfunction occurring within the lab for years.
Engineering the Illusion
Behind the scenes, the Edison was a mechanical disaster, plagued by overheating, broken parts, and inconsistent results. To maintain the illusion of success during demonstrations, Theranos secretly used modified commercial analyzers from companies like Siemens to process patient samples. Because these third-party machines required larger volumes of blood, Theranos employees had to dilute the finger-prick samples, which led to dangerously inaccurate readings. This deceptive practice was the core of the fraud, as the company continued to pitch a proprietary technology that was physically incapable of delivering the medical breakthroughs they promised to investors, while hiding the truth through elaborate laboratory workarounds.
The Walgreens Retail Gamble
Despite the technology’s failure, Holmes successfully pressured Walgreens into a massive partnership to launch Wellness Centers. The retail giant, fearing they might miss out on the next big tech revolution, ignored multiple red flags and skipped thorough due diligence. In 2013, Theranos began testing real patients in Arizona, despite knowing their machines provided unreliable data. This move shifted the company from a victimless corporate fraud to a public health crisis. Patients received incorrect diagnoses for serious conditions like cancer and HIV, illustrating the devastating real-world consequences of Holmes's fake it till you make it philosophy when applied to the strictly regulated field of medicine.
Cracks in the Facade
The turning point came when young employees like Tyler Shultz and Erika Cheung realized the extent of the lab's deception. They witnessed the manipulation of quality control data and the blatant disregard for patient safety. Despite the immense pressure and the looming threat of lawsuits from Theranos's aggressive legal team, these whistleblowers chose to act. They reached out to state regulators and eventually connected with investigative journalist John Carreyrou. Their bravery provided the internal evidence necessary to dismantle the wall of lies Holmes had built, marking the beginning of the end for the Silicon Valley unicorn that had once seemed untouchable to the media.
The Journalist's Pursuit
Wall Street Journal reporter John Carreyrou began a months-long investigation into Theranos after receiving a tip from a skeptical medical professional. He navigated a minefield of legal threats and intimidation tactics orchestrated by Holmes and her high-powered attorney, David Boies. Carreyrou meticulously interviewed former employees and medical experts, piecing together the technical impossibilities of the Edison. Despite Theranos’s attempts to kill the story by appealing directly to the Journal’s owner, Rupert Murdoch—who was a major investor in the company—Carreyrou’s blockbuster exposé was published in October 2015, shattering the company's carefully curated image and sparking a massive national scandal and federal investigation.
Regulatory Reckoning
Following the exposé, federal agencies including the CMS and FDA launched intensive investigations into Theranos’s labs. The CMS inspectors found immediate jeopardy to patient health and safety, leading to the revocation of the lab's certificates and a ban on Holmes operating a blood-testing lab for two years. The FDA ordered the company to stop using its proprietary Capillary Tube Nanotainer, which was the cornerstone of its finger-prick technology. These regulatory failures effectively neutralized Theranos’s business model, forcing the company to void years of test results and admit that its core technology was never viable for medical use, causing its valuation to plummet.
The Legal Collapse
The fallout from the regulatory findings led to a total collapse of investor confidence and a series of devastating lawsuits. In 2018, the SEC charged Holmes and Balwani with massive fraud for deceiving investors about the company's technology and financial performance. Shortly thereafter, the company officially dissolved, leaving behind a trail of financial ruin for its high-profile backers. Holmes and Balwani were subsequently indicted on multiple counts of wire fraud and conspiracy to commit wire fraud. The legal proceedings highlighted the depth of the deception, revealing how the duo had manipulated financial projections and lied about military contracts that never actually existed to gain funding.
Justice in the Courtroom
The trials of Elizabeth Holmes and Sunny Balwani became a symbol of the end of the fake it till you make it era in Silicon Valley. During her trial, Holmes attempted to deflect blame onto Balwani and claimed she genuinely believed in her vision, but the evidence of her direct involvement in the deception was overwhelming. In 2022, both were convicted on multiple fraud counts and sentenced to significant prison terms. The verdicts served as a landmark moment in corporate law, reinforcing the idea that even in the world of high-tech startups, founders cannot lie to investors or endanger the public with unproven medical claims.
A Cautionary Tale of Hubris
Bad Blood concludes as a powerful warning about the dangers of unchecked ambition and the God complex prevalent in tech culture. The Theranos saga exposes the vulnerabilities of a venture capital system that often prioritizes charisma and disruption over scientific rigor and ethical responsibility. It serves as a reminder that in industries like healthcare, where lives are at stake, the Silicon Valley mantra of moving fast and breaking things can have lethal consequences. The story of Elizabeth Holmes remains a definitive case study in how a mixture of corporate greed, institutional failure, and a culture of silence can lead to one of the biggest frauds in history.